<DOC>
	<DOCNO>NCT01952886</DOCNO>
	<brief_summary>The purpose study assess patient satisfaction , efficacy compliance granisetron patch versus ondansetron pill radiation induce nausea vomit malignant glioma patient receive six week radiation therapy ( RT ) concomitant temozolomide ( TMZ ) . Use patch may benefit brain tumor patient increase compliance . All eligible adult malignant glioma subject receive plan total dose 54-60 GY radiation 75 mg/m2 daily TMZ total six week . Subjects randomize receive either granisetron patch ondansetron three week . Weeks 3-6 , received medication . The granisetron transdermal delivery system ( supplied 52 cm^2 patch contain 34.3 mg granisetron - 3.1 mg/day ) apply per week 24 hour weekly radiation chemotherapy , ondansetron 8 mg oral tablet take day 30-60 minute prior dose chemotherapy . Subjects fill questionnaire regard effectiveness medication satisfaction , anti-emetic prefer . Safety assess throughout six week radiation clinical research nurse use Common Toxicity Criteria Adverse Events ( CTCAE ) , version 4.0 . All subject receive ondansetron Granisetron Transdermal Delivery System ( GTDS ) treatment include analysis treatment preference . However , efficacy safety analysis include subject receive ondansetron GTDS .</brief_summary>
	<brief_title>Patient Satisfaction , Efficacy Compliance Antiemetic Patch v Pill Malignant Glioma Patients</brief_title>
	<detailed_description>The primary objective study ass whether malignant glioma patient receive radiation therapy concomitant TMZ satisfy ondansetron granisetron patch prevention nausea vomit . The secondary objective 1 ) compare efficacy compliance granisetron patch ondansetron prevention nausea vomit 6 week RT concomitant TMZ , 2 ) ass safety granisetron patch prevent radiation induce nausea vomit primary glioma patient receive RT TMZ . All eligible subject receive plan total dose 54-60 GY radiation 75 mg/m2 temozolomide daily total six week . Subjects randomize receive one two treatment sequence antiemetic therapy prevention nausea vomit associate RT concomitant TMZ . Sequence # 1 involves administration ondansetron 3 week follow use granisetron patch 3 week ; whereas sequence # 2 involves use granisetron patch 3 week follow 3 week ondansetron . Toxicity assess week radiation therapy base Common Toxicity Criteria Adverse Events ( CTCAE ) , version 4.0 . The subject ask complete modify MASCC Antiemesis Tool ( MAT ) questionnaire baseline , day 2 , 4 , 7 week radiation therapy , well record use study medication antiemetic rescue medication take daily . At end week 3 &amp; 6 , subject ask fill Treatment Satisfaction Questionnaire Medication ask end week 6 choose antiemetic prefer .</detailed_description>
	<mesh_term>Glioma</mesh_term>
	<mesh_term>Antiemetics</mesh_term>
	<mesh_term>Granisetron</mesh_term>
	<mesh_term>Ondansetron</mesh_term>
	<criteria>1 . Patients must histologically confirm diagnosis malignant glioma ( Glioblastoma , gliosarcoma anaplastic astrocytoma , anaplastic oligodendroglioma ) may may chemotherapy naïve schedule receive radiotherapy ( total 60 GY ) concomitant daily temozolomide therapy ( dose 75 mg/m2 one complete six week cycle ) . 2 . Age ≥ 18 year 3 . Karnofsky ≥ 60 % 4 . Hematocrit &gt; 29 % , ANC &gt; 1,000 cells/mm3 , platelet &gt; 100,000 cells/ mm3 5 . Serum creatinine &lt; 1.4 mg/dl , serum SGOT bilirubin &lt; 1.5 time upper limit normal 6 . For patient corticosteroid , must stable dose 1 week prior entry , dose escalated entry dose level , clinically possible 7 . Ability willingness give inform consent 8 . If sexually active , patient take contraceptive measure duration treatment 9 . Negative serum pregnancy test 48 hour prior begin study drug 1 . Pregnancy breastfeed 2 . Comedication may interfere study result ; e.g. , immunesuppressive agent corticosteroid 3 . Inability unwillingness cooperate study procedures 4 . Prophylactic medication prevention nausea vomit 24 hour prior start radiation therapy full course radiation therapy prohibit , exception study drug . Corticosteroids allow treatment cerebral swelling . Rescue medication treatment nausea vomit permit radiation therapy discretion investigator 5 . Previous participation clinical trial involve granisetron 6 . Any vomiting , retch , NCI Common Toxicity Criteria version 4.0 grade 24 nausea 24 hour precede radiation chemotherapy 7 . Ongoing vomit organic etiology 8 . Radiotherapy abdomen within one week prior study 9 . Received granisetron within 14 day prior study enrollment 10 . Prior concomitant cancer chemotherapy radiotherapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>malignant glioma</keyword>
	<keyword>antiemetic</keyword>
	<keyword>ondansetron</keyword>
	<keyword>granisetron</keyword>
	<keyword>Preston Robert Tisch Brain Tumor Center</keyword>
	<keyword>Pro00041233</keyword>
	<keyword>Duke</keyword>
</DOC>